JP2024525559A - アルツハイマー病治療用バイオマーカー - Google Patents

アルツハイマー病治療用バイオマーカー Download PDF

Info

Publication number
JP2024525559A
JP2024525559A JP2024500220A JP2024500220A JP2024525559A JP 2024525559 A JP2024525559 A JP 2024525559A JP 2024500220 A JP2024500220 A JP 2024500220A JP 2024500220 A JP2024500220 A JP 2024500220A JP 2024525559 A JP2024525559 A JP 2024525559A
Authority
JP
Japan
Prior art keywords
subject
months
ratio
treatment
protofibril antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525559A5 (https=
Inventor
チャド スワンソン，
彰比古 小山
道雄 兼清
マイケル イリザリー，
リン クレイマー，
ジューン カプロウ，
デイビッド バーベル，
ショバ ダッダ，
パラヴィ サチデヴ，
ラリサ レイダーマン，
誠一 早戸
イシャニ ランドリー，
ロバート ゴードン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2024525559A publication Critical patent/JP2024525559A/ja
Publication of JP2024525559A5 publication Critical patent/JP2024525559A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2024500220A 2021-07-09 2022-07-08 アルツハイマー病治療用バイオマーカー Pending JP2024525559A (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202163220434P 2021-07-09 2021-07-09
US63/220,434 2021-07-09
US202163203444P 2021-07-22 2021-07-22
US63/203,444 2021-07-22
US202163263255P 2021-10-29 2021-10-29
US63/263,255 2021-10-29
US202163263928P 2021-11-11 2021-11-11
US63/263,928 2021-11-11
US202163264551P 2021-11-24 2021-11-24
US63/264,551 2021-11-24
US202263306028P 2022-02-02 2022-02-02
US63/306,028 2022-02-02
US202263269372P 2022-03-15 2022-03-15
US63/269,372 2022-03-15
US202263364618P 2022-05-12 2022-05-12
US63/364,618 2022-05-12
PCT/US2022/073576 WO2023283650A1 (en) 2021-07-09 2022-07-08 Biomarkers for alzheimer's disease treatment

Publications (2)

Publication Number Publication Date
JP2024525559A true JP2024525559A (ja) 2024-07-12
JP2024525559A5 JP2024525559A5 (https=) 2025-07-16

Family

ID=83232761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500220A Pending JP2024525559A (ja) 2021-07-09 2022-07-08 アルツハイマー病治療用バイオマーカー

Country Status (11)

Country Link
US (1) US20250163135A1 (https=)
EP (1) EP4367516A1 (https=)
JP (1) JP2024525559A (https=)
KR (1) KR20240033017A (https=)
AU (1) AU2022307687A1 (https=)
CA (1) CA3225302A1 (https=)
CL (1) CL2024000063A1 (https=)
IL (1) IL309468A (https=)
MX (1) MX2023015183A (https=)
TW (1) TW202317192A (https=)
WO (1) WO2023283650A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024064897A1 (en) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases
WO2025019457A1 (en) * 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025260029A1 (en) 2024-06-14 2025-12-18 Eisai R&D Management Co., Ltd. Method for quantifying amyloid beta protofibril
CN118777453B (zh) * 2024-06-25 2025-04-08 上海交通大学医学院附属瑞金医院 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
LT2448968T (lt) 2009-06-29 2021-05-10 Bioarctic Ab Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
RS67249B1 (sr) 2020-03-20 2025-10-31 Eisai R&D Man Co Ltd Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe
IL296992A (en) * 2020-04-03 2022-12-01 Alector Llc Methods for using anti-trem2 antibodies
TWI843040B (zh) * 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途

Also Published As

Publication number Publication date
CA3225302A1 (en) 2023-01-12
MX2023015183A (es) 2024-03-14
CL2024000063A1 (es) 2024-08-02
AU2022307687A1 (en) 2024-01-04
KR20240033017A (ko) 2024-03-12
EP4367516A1 (en) 2024-05-15
US20250163135A1 (en) 2025-05-22
TW202317192A (zh) 2023-05-01
IL309468A (en) 2024-02-01
WO2023283650A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
Frisoni et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
JP2024525559A (ja) アルツハイマー病治療用バイオマーカー
US20220372123A1 (en) Anti-beta-amyloid antibody for treating alzheimer's disease
JP7541505B2 (ja) アルツハイマー病の治療及び予防方法
JP2025506389A (ja) ｐ－タウ１８１レベルを使用した治療方法
JP2017537905A (ja) アルツハイマー病の治療法
JP2024509960A (ja) 抗アミロイドベータ抗体及びその使用
JP2025539394A (ja) タウｐｅｔレベルを使用する治療の方法
JP2024532438A (ja) 抗Ａβプロトフィブリル抗体の皮下製剤及びその使用方法
CN117940773A (zh) 用于阿尔茨海默病治疗的生物标记物
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
CN118786141A (zh) 使用p-tau181水平的治疗方法
WO2026015877A1 (en) Fluid biomarker
KR20260038283A (ko) 항미생물 펩티드
CN121335711A (zh) 使用抗Aβ初原纤维抗体的治疗方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250708